Published in:
01-07-2016 | Original Article
Long-Term Follow-Up of Patients Treated with Infliximab for Ulcerative Colitis: Predictive Factors of Response—An Observational Study
Authors:
Orlando García-Bosch, Montserrat Aceituno, Ingrid Ordás, Josefina Etchevers, Miquel Sans, Faust Feu, Julián Panés, Elena Ricart
Published in:
Digestive Diseases and Sciences
|
Issue 7/2016
Login to get access
Abstract
Aim
To evaluate the early and long-term efficacy of infliximab in ulcerative colitis and to determine predictors of response and colectomy.
Methods
This is an ambidirectional cohort study in a tertiary referral center including patients who started infliximab within 2005 and 2008 and monitored until 2014. Efficacy was evaluated by partial Mayo scores at weeks 2, 4, 8, 30, and 54. Long-term treatment maintenance with infliximab and colectomy requirements were recorded.
Results
Fifty-three patients were included with a median follow-up of 69.5 months. Clinical remission at the time point assessments was 40.8, 47.2, 54.7, 54.7, and 49.1 %. At the time of maximal follow-up, the proportion of patients under infliximab maintenance was 24.5 %. A higher level of albumin (OR 1.4, CI 95 % 1.06–1.8; p = 0.017) was predictive of a higher remission rate at week 8. Concomitant immunomodulators beyond 6 months were predictive of infliximab’s long-term maintenance (OR 15.8, CI 95 % 1.8–135.4; p = 0.012). Colectomy was required in 41.5 %. Factors associated with a higher rate of colectomy at week 54 were previous treatment with cyclosporine (OR 3.4, CI 95 % 1.2–9.7; p = 0.012), absence of response at week 8 (OR 10.3, CI 95 % 3.3–31.7; p < 0.001), and not receiving concomitant immunomodulators (OR 4.1, CI 95 % 1.8–9; p = 0.002). Colectomy rates within the first 54 weeks were closely dependent on the number of variables present: none (0 %), 1 (26.3 %), 2 (71.4 %), or 3 (100 %) of them (log rank <0.0001).
Conclusions
Low albumin, previous treatment with cyclosporine, absence of a concomitant immunomodulator, and lack of response at week 8 negatively affected the efficacy of infliximab in ulcerative colitis.